Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cormedix Inc (CRMD)

Cormedix Inc (CRMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cormedix Inc 389 INTERPACE PKWY SUITE 450 PARSIPPANY NJ 07054 USA

www.cormedix.com Employees: 191 P: 908-517-9500 F: 908-375-8272

Sector:

Medical

Description:

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog

Key Statistics

Overview:

Market Capitalization, $K 519,359
Enterprise Value, $K 374,519
Shares Outstanding, K 79,050
Float, K 76,599
% Float 96.90%
Short Interest, K 15,846
Short Float 20.05%
Days to Cover 7.93
Short Volume Ratio 0.70
% of Insider Shareholders 3.10%
% of Institutional Shareholders 34.18%

Financials:

Annual Sales, $ 311,710 K
Annual Net Income, $ 163,060 K
Last Quarter Sales, $ 128,620 K
Last Quarter Net Income, $ 14,020 K
EBIT, $ 150,150 K
EBITDA, $ 165,540 K

Growth:

1-Year Return -2.52%
3-Year Return 55.32%
5-Year Return -30.84%
5-Year Revenue Growth 129,779.16%
5-Year Earnings Growth 336.36%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.61 on 03/05/26
Next Earnings Date 05/05/26
Earnings Per Share ttm 1.76
EPS Growth vs. Prev Qtr 7.02%
EPS Growth vs. Prev Year 177.27%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 03/26/19

CRMD Ratios

Ratio
Price/Earnings ttm 3.81
Price/Earnings forward 9.85
Price/Earnings to Growth N/A
Return-on-Equity % 52.30%
Return-on-Assets % 29.46%
Profit Margin % 52.31%
Debt/Equity 0.00
Price/Sales 1.70
Price/Cash Flow 3.28
Price/Book 1.30
Book Value/Share 5.14
Interest Coverage 54.96
60-Month Beta 1.31
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.